The gynecologic cancer investigator faces many challenges. Successful career development requires choosing commitments wisely after completing clinical training, earning board certification, and completing a fellowship. Finding protected time for research requires cooperation from the department chair, and lining up funding for research begins with the researcher's own institution and stretches as far away as European funding groups. State and federal agencies, particularly the National Cancer Institute, offer a wide range of opportunities to obtain funding and to seek information about how to shape research and applications. Professional societies and charities also fund initiatives. Advantages of working with a clinical trials cooperative group include large fund reserves, centralized data management, statistical support, the potential of rapid accrual from multiple sites, and an established infrastructure. Seeking multiple sources of funding probably is wise, and meeting grant deadlines requires organization and planning. Working with industry requires legal review; avoiding conflict of interest; working with appropriate federal agencies, such as the U.S. Food and Drug Administration; and careful review of contractual agreements. Today's successful investigator who wants to reduce the burden of cervical cancer seeks funding from multiple sources, including industry; makes use of the consulting advice available from state and federal governments and nonprofit organizations; establishes clear channels of communication; and consults appropriate legal and scientific advisors in planning a trial. Developing a successful academic career with a focus on research in gynecologic cancer requires planning and a supportive environment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/cncr.11683 | DOI Listing |
Ann Med
December 2025
Department of Assisted Reproductive Centre, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, China.
Background: Butyrate may inhibit SARS-CoV-2 replication and affect the development of COVID-19. However, there have been no systematic comprehensive analyses of the role of butyrate metabolism-related genes (BMRGs) in COVID-19.
Methods: We performed differential expression analysis of BMRGs in the brain, liver and pancreas of COVID-19 patients and controls in GSE157852 and GSE151803.
Clin Transl Med
March 2025
Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.
Keio J Med
March 2025
Center for Hereditary Breast and Ovarian Cancer Syndrome, Keio University Hospital, Tokyo, Japan.
Hereditary breast and ovarian cancer syndrome (HBOC) is traditionally associated with mutations in the BRCA1 and BRCA2 genes, predominantly impacting breast, ovarian, pancreatic, and prostate cancers. However, recent research suggests that these mutations may also predispose carriers to a broader spectrum of malignancies, including biliary tract, cervical, colorectal, endometrial, esophageal, and gastric cancers. This review presents findings from extensive datasets, including a significant study from a nationwide Japanese biobank that examined cancer risks in 63,828 patients and 37,086 controls.
View Article and Find Full Text PDFUnlabelled: supporting clinical decision-making, diagnosis, and treatment. The study aims to compare the performance of ChatGPT-4o (Omni) and Gemini-pro in answering clinical questions and case scenarios related to gynecological oncology and to assess the consistency of their long-term responses.
Methods: A two-phase comparative analysis was conducted.
Pathol Res Pract
March 2025
Biochemistry Dept., Faculty of Pharmacy, Ain Shams University, Abassia, Cairo 11566, Egypt. Electronic address:
Background: The infiltration of lateral lymph nodes (LLN) plays a crucial role in the staging and treatment of individuals with locally advanced rectal cancer (LARC). This meta-analysis aimed to compare the efficacy of extended mesorectal excision (eTME) versus traditional mesorectal excision (TME-alone) in patients with clinically enlarged (LLN) concomitant neoadjuvant chemoradiation.
Methods: This study is registered with PROSPERO (CRD42023457805).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!